title: MRI as a Novel In Vivo Approach for Assessing Structural Changes of Chlamydia Pathology in a Mouse Model.
abstract: Chlamydia trachomatis is among the most prevalent of sexually transmitted diseases. While Chlamydia infection is a reportable event and screening has increased over time, enhanced surveillance has not resulted in a reduction in the rate of infections, and Chlamydia infections frequently recur. The development of a preventative vaccine for Chlamydia may be the only effective approach for reducing infection and the frequency of pathological outcomes. Current vaccine research efforts involve time consuming and/or invasive approaches for assessment of disease state, and MRI presents a clinically translatable method for assessing infection and related pathology both quickly and non-invasively. Longitudinal T2-weighted MRI was performed over 63 days on both control or Chlamydia muridarum challenged mice, either with or without elementary body (EB) immunization, and gross necropsy was performed on day 65. A scoring system was developed to assess the number of regions affected by Chlamydia pathology and was used to document pathology over time and at necropsy. The scoring system documented increasing incidence of pathology in the unimmunized and challenged mice (significantly greater compared to the control and EB immunized-challenged groups) by 21 days post-challenge. No differences between the unchallenged and EB immunized-challenged mice were observed. MRI scores at Day 63 were consistently higher than gross necropsy scores at Day 65, although two of the three groups of mice showed no significant differences between the two techniques. In this work we describe the application of MRI in mice for the potential evaluation of disease pathology and sequelae caused by C. muridarum infection and this technique's potential for evaluation of vaccines for Chlamydia.
authors.affiliation: Department of Translational Imaging Biomarkers, MRL (West Point, PA), Merck & Co., Inc., Kenilworth, New Jersey, United States of America.
authors.forename: Catherine D G
authors.identifier: http://orcid.org/0000-0001-9826-3164
authors.initials: CD
authors.lastname: Hines
authors.affiliation: Department of Biometrics Research, MRL (Rahway, NJ), Merck & Co., Inc., Kenilworth, New Jersey, United States of America.
authors.forename: Shubing
authors.initials: S
authors.lastname: Wang
authors.affiliation: Department of Translational Imaging Biomarkers, MRL (West Point, PA), Merck & Co., Inc., Kenilworth, New Jersey, United States of America.
authors.forename: Xiangjun
authors.initials: X
authors.lastname: Meng
authors.affiliation: Department of Vaccines Early Discovery, MRL (West Point, PA), Merck & Co., Inc., Kenilworth, New Jersey, United States of America.
authors.forename: Julie M
authors.initials: JM
authors.lastname: Skinner
authors.affiliation: Global Project Leadership, Sanofi Pasteur, Swiftwater, Pennsylvania, United States of America.
authors.forename: Jon H
authors.initials: JH
authors.lastname: Heinrichs
authors.affiliation: Pharmaceutical Sciences Analytical Research & Development, Pfizer, Andover, Massachusetts, United States of America.
authors.forename: Jeffrey G
authors.initials: JG
authors.lastname: Smith
authors.affiliation: Department of Vaccines Early Discovery, MRL (West Point, PA), Merck & Co., Inc., Kenilworth, New Jersey, United States of America.
authors.forename: Melissa A
authors.initials: MA
authors.lastname: Boddicker
mesh_terms: D000818:Animals; D002690:Chlamydia Infections / Q000000981:diagnostic imaging* / Q000382:microbiology; D004195:Disease Models, Animal; D006367:HeLa Cells; D006801:Humans; D008279:Magnetic Resonance Imaging; D051379:Mice